Clinical Observation of Compound Glycyrrhizin Combination with Acyclovir in the Treatment of Children with Infectious Mononucleosis
10.6039/j.issn.1001-0408.2015.36.13
- VernacularTitle:复方甘草酸苷联合阿昔洛韦治疗小儿传染性单核细胞增多症的临床观察
- Author:
Qixiang ZHANG
;
Jianhua ZHANG
- Publication Type:Journal Article
- Keywords:
Infectious mononucleosis;
Compound glycyrrhizin;
Acyclovir;
Efficacy;
Safety
- From:
China Pharmacy
2015;26(36):5080-5082
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy and safety of compound glycyrrhizin combined with acyclovir in the treatment of children with infectious mononucleosis. METHODS:90 children with infectious mononucleosis were randomly divid-ed into control group and research group. Control group was given Acyclovir injection 10 mg/(kg·d)adding into 150 ml 5% Glu-cose solution by intravenous infusion,twice a day. Research group was additionally given Compound glycyrrhizin injection 2-4 ml/kg,adding into 150 ml 5% Glucose solution by intravenous infusion,twice a day. The treatment course for both group was 2 weeks. Clinical efficacy,hospitalization time,improvement time of clinical symptoms,T lymphocyte subsets(CD3+,CD4+,CD8+ and CD4+/CD8+)before and after treatment and incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in research group was significantly higher than control group,hospitalization time and improvement time of clinical symptoms were significantly better than control group,the differences were statistically significant(P<0.05). After treatment,CD3+ and CD8+were significantly lower than before,and research group was lower than control group,CD4+and CD4+/CD8+were significantly high-er than before,and research group was higher than before,the differences were statistically significant(P<0.05). There was no sig-nificant difference in the incidence of adverse reactions between 2 groups(P>0.05). CONCLUSIONS:Compound glycyrrhizin combined with acyclovir has better efficacy than only acyclovir in the treatment of children with infectious mononucleosis,with similar safety.
